Lindsey Yourman
speaker
182 appearances
1 recordings
1 series
first heard Nov 2020
last heard Nov 2020
Lindsey Yourman’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
So that comes up a lot for me.
That's
I think in all of these interventions that we're talking about, one of the remarkable things to consider is we're talking about times to benefit that are at least weeks and then sometimes years, but the time to harm is often right away from side effects.
So
thinking about the trade offs uh is really important.
I think with diabetes, the big one with like type glycemic control that we all experience is uh if we try to do that, we can bottom someone out and they can have a hypoglycemic event that could cause a fall and a major injury or just the burden on their quality of life of checking their blood sugar all day.
versus they may not benefit from reduced eye disease for many years to come.
So they're they may have some harm before they have benefit.
Well, uh we often prescribe statins in patients that aren't having any symptoms from cardiovascular disease.
So we're starting with well patients.
And that's that
Primary prevention.
And the idea is that we're gonna prevent some cardiovascular event in the future.
But we all know that our patients, many of our patients, do report some musculoskeletal side effects from statins.
They'll talk about myalgias.
And there's some debate about how much statins really cause myalgias, but
We all know from clinical experience that for some patients it's very real for them at least that they do experience myalgias as well as just the burden of additional medication.
So uh with statins, which we prescribe so frequently, I found myself wondering how long will it take for my patients to benefit from prescribing the statin?
When when does the payoff come?
Yeah, so in this paper, the really interesting thing is the data kind of limited us to really focus on a hodgepodge of cardiovascular vents as the payoff.
Showing 41–60 of 182 · page 3 of 10
← Previous
Next →